In the latest trading session, 0.66 million ARS Pharmaceuticals Inc (NASDAQ:SPRY) shares changed hands as the company’s beta touched 0.99. With the company’s most recent per share price at $12.04 changed hands at -$0.98 or -7.53% at last look, the market valuation stands at $1.17B. SPRY’s current price is a discount, trading about -53.74% off its 52-week high of $18.51. The share price had its 52-week low at $6.17, which suggests the last value was 48.75% up since then. When we look at ARS Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.41 million shares, with the 3-month average coming to 1.33 million.
Analysts gave the ARS Pharmaceuticals Inc (SPRY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SPRY as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY was in red as seen in intraday trades today. With action -16.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 14.12%, with the 5-day performance at -16.68% in the red. However, in the 30-day time frame, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 14.12% up. Looking at the short shares, we see there were 14.81 million shares sold at short interest cover period of 10.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 26, meaning bulls need an upside of 53.69% from its recent market value. According to analyst projections, SPRY’s forecast low is 22 with 30 as the target high. To hit the forecast high, the stock’s price needs a -149.17% plunge from its current level, while the stock would need to soar -82.72% for it to hit the projected low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Data shows that the ARS Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 14.78% over the past 6 months, a -1.75% in annual growth rate that is considerably lower than the industry average of 17.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -1.44%. The 2025 estimates are for ARS Pharmaceuticals Inc earnings to increase by 2.82%.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 23.19% of ARS Pharmaceuticals Inc shares while 68.64% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 89.36%. There are 68.64% institutions holding the ARS Pharmaceuticals Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 11.4409% of the shares, roughly 11.08 million SPRY shares worth $94.27 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.86 shares estimated at $22.23 million under it, the former controlled 1.92% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.42% of the shares, roughly 1.38 shares worth around $16.49 million.
